Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Cidara Therapeutics Inc Stock

Price
Target price
€0.48

€0.48

-0.620%
-0.003
-0.620%
-
 
23.04.24 / Tradegate WKN: A14R2R / Name: Cidara / Stock / Biotechnology & Medical Research / Micro Cap / We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Cidara Therapeutics Inc in the next few years
Wizard

Financial data and news for Cidara

sharewise wants to provide you with the best news and tools for Cidara, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer: https://cdn.content.foolcdn.com/images/1umn9qeh/production/280eca1b4ecd8cc2401a2f4b2c3a68395e00dc85-1401x1251.png?w=1401&h=1251
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer

On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed a purchase of 520,310 shares of Cidara Therapeutics (NASDAQ:CDTX), increasing its position value by approximately $167.48

TheMotleyFool 
0 20.11.25
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.: https://g.foolcdn.com/editorial/images/842730/biotech-pharma-researchers-talk-lab.jpg
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.

Just prior to last week's takeover news, Cidara Therapeutics (NASDAQ: CDTX) was already one of the year's top-performing stocks. Trading in the mid-$20s at the start of 2025, by mid-November, this

TheMotleyFool 
0 20.11.25
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover: https://cdn.content.foolcdn.com/images/1umn9qeh/production/1a599f395be31e2f508c3aa7decb988f9ce983b7-1401x1251.png?w=1401&h=1251
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover

California-based TCG Crossover Management fully exited its position in Cidara Therapeutics (NASDAQ:CDTX) during the third quarter, reducing its holdings by 1 million shares in a move valued at

TheMotleyFool 
0 17.11.25
Why Cidara Therapeutics Stock Crushed It Today: https://g.foolcdn.com/editorial/images/837288/healthcare-professional-inspecting-charts.jpg
Why Cidara Therapeutics Stock Crushed It Today

The leading pipeline drug being developed by Cidara Therapeutics (NASDAQ: CDTX) got a real boost from a regulator on Thursday, and the biotech's share price moved accordingly. Cidara's stock closed

TheMotleyFool 
0 10.10.25
Why Cidara Therapeutics Was Such a Healthy Stock Today: https://g.foolcdn.com/editorial/images/835323/child-receiving-a-vaccination-shot-from-a-healthcare-professional.jpg
Why Cidara Therapeutics Was Such a Healthy Stock Today

Cidara Therapeutics (NASDAQ: CDTX) had some encouraging news to deliver at the end of the trading week, and investors traded the biotech's stock up as a result. It closed Friday nearly 7% higher in

TheMotleyFool 
0 26.09.25
Cidara (CDTX) Q2 Cash Surges 163%
Cidara (CDTX) Q2 Cash Surges 163%

Cidara Therapeutics (NASDAQ:CDTX), a biotechnology company focused on the development of innovative therapies for infectious diseases and oncology, released its second-quarter 2025 earnings on

TheMotleyFool 
0 07.08.25